• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雄激素剥夺治疗后前列腺癌中生长抑素受体亚型的免疫组化表达和定位。

Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer.

机构信息

Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Torrette, Ancona, Italy.

出版信息

Cell Oncol (Dordr). 2011 Jun;34(3):235-43. doi: 10.1007/s13402-011-0031-y. Epub 2011 Apr 30.

DOI:10.1007/s13402-011-0031-y
PMID:21533650
Abstract

OBJECTIVE

The aim was to examine the expression and localization of the five somatostatin receptors (termed SSTR1 to 5) in radical prostatectomies (RPs) from patients with prostatic adenocarcinoma (PCa) under complete androgen ablation (CAA) before operation.

MATERIAL

The five SSTRs were evaluated in the epithelial, smooth muscle and endothelial cells of normal-looking epithelium (Nep), high-grade prostatic intraepithelial neoplasia (HGPIN) and PCa in 20 RPs with clinically detected PCa from patients under CAA. Twenty RPs with clinically detected PCa from hormonally untreated patients were used as control group.

RESULTS

Concerning the secretory cells (i) Membrane staining was seen for SSTR3 and SSTR4; the mean percentages of positive cells, higher in SSTR3 than in SSTR4, decreased sharply in HGPIN and PCa compared with Nep; the mean percentages in the androgen ablated group were 30% to 90% lower than in the untreated; (ii) Cytoplasmic staining was seen for all five SSTRs; the mean percentages of positive cells in Nep, HGPIN and PCa of the untreated group were similar, and in general as high as 80% or more; in the treated group, the Nep values were similar to those in the untreated, whereas the values in HGPIN and PCa were lower for SSTR1, three and five, with a decrease of 30% for SSTR1; (iii) Nuclear staining was seen with SSTR4 and SSTR5, the mean percentages for the former being much lower than for the latter; treatment affected both HGPIN and PCa, whose proportions of stained cells were 30% to 55% lower than in the untreated group. Cytoplasmic staining in the basal cells was seen for all five SSTRs, both in Nep and HGPIN. The values in the treated group were lower than in the other, the difference between the two group being in general comprised between 10% and 40%. Treatment did not affect SSTR staining in the smooth muscle and endothelial cells.

CONCLUSIONS

The present study expands our knowledge on the expression and localization of the five SSTRs in the prostate following CAA.

摘要

目的

研究完全雄激素阻断(CAA)前接受根治性前列腺切除术(RP)的前列腺腺癌(PCa)患者的前列腺组织中五种生长抑素受体(SSTR1 至 5)的表达和定位。

材料

在 20 例接受 CAA 的临床诊断为 PCa 的 RP 中,评估了正常外观上皮(Nep)、高级别前列腺上皮内瘤变(HGPIN)和 PCa 中的上皮细胞、平滑肌细胞和内皮细胞中这五种 SSTR。20 例接受激素治疗的 PCa 患者的 RP 作为对照组。

结果

关于分泌细胞(i)SSTR3 和 SSTR4 存在膜染色;与 Nep 相比,SSTR3 的阳性细胞百分比更高,而在 HGPIN 和 PCa 中则急剧下降;CAA 组的平均百分比比未治疗组低 30%至 90%;(ii)所有五种 SSTR 均存在细胞质染色;未治疗组 Nep、HGPIN 和 PCa 的阳性细胞百分比相似,通常高达 80%或更高;在治疗组中,Nep 值与未治疗组相似,而 HGPIN 和 PCa 中 SSTR1、3 和 5 的值较低,SSTR1 降低了 30%;(iii)SSTR4 和 SSTR5 存在核染色,前者的平均百分比明显低于后者;治疗影响 HGPIN 和 PCa,其染色细胞的比例比未治疗组低 30%至 55%。五种 SSTR 均在 Nep 和 HGPIN 的基底细胞中存在细胞质染色。治疗组的数值低于其他组,两组之间的差异通常在 10%至 40%之间。治疗不影响平滑肌和内皮细胞中的 SSTR 染色。

结论

本研究扩展了我们对 CAA 后前列腺中五种 SSTR 表达和定位的认识。

相似文献

1
Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer.雄激素剥夺治疗后前列腺癌中生长抑素受体亚型的免疫组化表达和定位。
Cell Oncol (Dordr). 2011 Jun;34(3):235-43. doi: 10.1007/s13402-011-0031-y. Epub 2011 Apr 30.
2
Immunohistochemical expression and localization of somatostatin receptor subtypes in androgen ablated prostate cancer.雄激素剥夺治疗后前列腺癌中生长抑素受体亚型的免疫组化表达和定位。
Anal Cell Pathol (Amst). 2010;33(1):27-36. doi: 10.3233/ACP-CLO-2010-0529.
3
Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation.免疫组织化学表达和定位在前列腺癌神经内分泌分化中的生长抑素受体亚型。
Int J Immunopathol Pharmacol. 2010 Apr-Jun;23(2):511-22. doi: 10.1177/039463201002300213.
4
Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer.免疫组化检测偶然前列腺癌患者行膀胱前列腺切除术前列腺组织中生长抑素受体亚型的表达
BJU Int. 2010 Oct;106(7):1072-80. doi: 10.1111/j.1464-410X.2010.09238.x. Epub 2010 Mar 1.
5
Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma.激素难治性(去势抵抗性)前列腺癌中的生长抑素受体亚型。
Asian J Androl. 2011 Mar;13(2):242-7. doi: 10.1038/aja.2010.100. Epub 2010 Dec 13.
6
Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies.ELAV 样蛋白 HuR 的过表达与萎缩、高级别前列腺上皮内瘤变和膀胱前列腺切除术中偶发前列腺癌中 COX-2 表达增加有关。
Eur Urol. 2009 Jul;56(1):105-12. doi: 10.1016/j.eururo.2008.04.043. Epub 2008 Apr 30.
7
Immunohistochemical expression and localization of somatostatin receptors in normal prostate, high grade prostatic intraepithelial neoplasia and prostate cancer and its many faces.在正常前列腺、高级别前列腺上皮内瘤变和前列腺癌及其多种形态中生长抑素受体的免疫组化表达和定位。
J Biol Regul Homeost Agents. 2012 Apr-Jun;26(2):181-92.
8
Immunohistochemical expression of prostate stem cell antigen in cystoprostatectomies with incidental prostate cancer.前列腺干细胞抗原在伴发偶发性前列腺癌的膀胱前列腺切除术中的免疫组化表达
Int J Immunopathol Pharmacol. 2009 Jul-Sep;22(3):755-62. doi: 10.1177/039463200902200321.
9
HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.膀胱前列腺切除术中偶然发现的pT2a Gleason评分6分前列腺癌中的HER2表达及基因扩增:与临床检测的雄激素依赖性和雄激素非依赖性癌症的比较
Hum Pathol. 2006 Sep;37(9):1137-44. doi: 10.1016/j.humpath.2006.04.004. Epub 2006 Jun 21.
10
Immunohistochemical expression of prostate tumour overexpressed 1 (PTOV1) in atypical adenomatous hyperplasia (AAH) of the prostate: additional evidence linking (AAH) to adenocarcinoma.前列腺肿瘤过表达 1(PTOV1)在前列腺不典型腺瘤样增生(AAH)中的免疫组化表达:将(AAH)与腺癌联系起来的更多证据。
Cell Oncol (Dordr). 2013 Feb;36(1):37-42. doi: 10.1007/s13402-012-0111-7. Epub 2012 Nov 7.

引用本文的文献

1
Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors.神经内分泌肿瘤中生长抑素受体表达与临床结局的关联
Pancreas. 2016 Nov;45(10):1386-1393. doi: 10.1097/MPA.0000000000000700.
2
Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse.前列腺癌中生长抑素受体2亚型的缺失与侵袭性癌症表型、高肿瘤细胞增殖相关,并可预测早期转移和生化复发。
PLoS One. 2014 Jul 10;9(7):e100469. doi: 10.1371/journal.pone.0100469. eCollection 2014.
3
Down-regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5: a novel mechanism for inhibition of cellular proliferation and insulin secretion by somatostatin.

本文引用的文献

1
Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation.免疫组织化学表达和定位在前列腺癌神经内分泌分化中的生长抑素受体亚型。
Int J Immunopathol Pharmacol. 2010 Apr-Jun;23(2):511-22. doi: 10.1177/039463201002300213.
2
Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer.免疫组化检测偶然前列腺癌患者行膀胱前列腺切除术前列腺组织中生长抑素受体亚型的表达
BJU Int. 2010 Oct;106(7):1072-80. doi: 10.1111/j.1464-410X.2010.09238.x. Epub 2010 Mar 1.
3
Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and phosphotyrosine phosphatase SHP-1 (PTPN6) according to tumor progression.
生长抑素受体亚型 5 下调胰腺十二指肠同源盒-1:生长抑素抑制细胞增殖和胰岛素分泌的新机制。
Front Physiol. 2014 Jun 25;5:226. doi: 10.3389/fphys.2014.00226. eCollection 2014.
肿瘤性前列腺组织中,生长抑素受体2(SSTR2)和磷酸酪氨酸磷酸酶SHP-1(PTPN6)的表达模式会随肿瘤进展而有所不同。
Adv Urol. 2009;2009:723831. doi: 10.1155/2009/723831. Epub 2009 Apr 12.
4
Immunohistochemical detection and localization of somatostatin receptor subtypes in prostate tissue from patients with bladder outlet obstruction.膀胱出口梗阻患者前列腺组织中生长抑素受体亚型的免疫组织化学检测与定位
Cell Oncol. 2008;30(6):473-82. doi: 10.3233/clo-2008-0433.
5
Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy.神经内分泌肿瘤中2A 型生长抑素受体免疫组织化学:一种与生长抑素受体闪烁扫描相关的评分系统建议
Mod Pathol. 2007 Nov;20(11):1172-82. doi: 10.1038/modpathol.3800954. Epub 2007 Sep 14.
6
Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study.长效释放奥曲肽与他莫昔芬联合应用于晚期肝细胞癌患者的疗效:一项随机多中心III期研究
Br J Cancer. 2007 Sep 3;97(5):582-8. doi: 10.1038/sj.bjc.6603901. Epub 2007 Aug 7.
7
Effect of chemotherapy on somatostatin receptor detection with octreotide scintigraphy in hormone-refractory prostate cancer patients.
Anticancer Res. 2006 May-Jun;26(3B):2233-5.
8
Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: an immunohistochemical analysis.阿尔茨海默病脑内生长抑素受体亚型(SSTR1 - 5)的表达:免疫组织化学分析
Neuroscience. 2005;134(2):525-38. doi: 10.1016/j.neuroscience.2005.04.001.
9
Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma.生长抑素受体在正常及肝硬化人肝脏和肝细胞癌中的表达
Gut. 2004 Aug;53(8):1180-9. doi: 10.1136/gut.2003.036053.
10
Somatostatin receptors: from basic science to clinical approach--thyroid.生长抑素受体:从基础科学到临床应用——甲状腺
Dig Liver Dis. 2004 Feb;36 Suppl 1:S86-92. doi: 10.1016/j.dld.2003.11.018.